BACKGROUND: Gremlin 1 (GREM1) is a bone morphogenetic protein antagonist and a novel proangiogenic factor. Our aim was to evaluate the prognostic value of GREM1 expression and GREM1-related factors in tumor-associated angiogenesis in pancreatic neuroendocrine tumors (NETs). METHODS: The immunohistochemical expression of GREM1 and microvessel density (MVD) were examined in 35 patients with pancreatic NETs and then compared with other clinicopathologic characteristics, including the World Health Organization classification. RESULTS: The presence of expression of GREM1 (p = 0.016) and high MVD (p = 0.020) were significant and favorable prognostic factors. Moreover, GREM1 expression was significantly associated with high MVD (p = 0.011). MVD was significantly higher in well-differentiated NETs than in well-differentiated or poorly differentiated neuroendocrine carcinomas (p < 0.001). CONCLUSIONS: GREM1 expression was correlated with tumor-associated angiogenesis and was found to be a novel prognostic marker in pancreatic NETS. Our data support a tumor suppressor role of GREM1 in pancreatic NETs.
BACKGROUND:Gremlin 1 (GREM1) is a bone morphogenetic protein antagonist and a novel proangiogenic factor. Our aim was to evaluate the prognostic value of GREM1 expression and GREM1-related factors in tumor-associated angiogenesis in pancreatic neuroendocrine tumors (NETs). METHODS: The immunohistochemical expression of GREM1 and microvessel density (MVD) were examined in 35 patients with pancreatic NETs and then compared with other clinicopathologic characteristics, including the World Health Organization classification. RESULTS: The presence of expression of GREM1 (p = 0.016) and high MVD (p = 0.020) were significant and favorable prognostic factors. Moreover, GREM1 expression was significantly associated with high MVD (p = 0.011). MVD was significantly higher in well-differentiated NETs than in well-differentiated or poorly differentiated neuroendocrine carcinomas (p < 0.001). CONCLUSIONS:GREM1 expression was correlated with tumor-associated angiogenesis and was found to be a novel prognostic marker in pancreatic NETS. Our data support a tumor suppressor role of GREM1 in pancreatic NETs.
Authors: P B Vermeulen; G Gasparini; S B Fox; M Toi; L Martin; P McCulloch; F Pezzella; G Viale; N Weidner; A L Harris; L Y Dirix Journal: Eur J Cancer Date: 1996-12 Impact factor: 9.162
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: A Couvelard; D O'Toole; H Turley; R Leek; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella Journal: Br J Cancer Date: 2005-01-17 Impact factor: 7.640
Authors: M Suzuki; H Shigematsu; D S Shames; N Sunaga; T Takahashi; N Shivapurkar; T Iizasa; E P Frenkel; J D Minna; T Fujisawa; A F Gazdar Journal: Br J Cancer Date: 2005-10-31 Impact factor: 7.640
Authors: Imad Siddique; Simon P Curran; Ayesha Ghayur; Limin Liu; Wei Shi; Catherine M Hoff; Azim S Gangji; K Scott Brimble; Peter J Margetts Journal: Am J Pathol Date: 2014-09-03 Impact factor: 4.307
Authors: Jiang Ren; Marcel Smid; Josephine Iaria; Daniela C F Salvatori; Hans van Dam; Hong Jian Zhu; John W M Martens; Peter Ten Dijke Journal: Breast Cancer Res Date: 2019-09-18 Impact factor: 6.466
Authors: Christopher W Resnyk; Chuming Chen; Hongzhan Huang; Cathy H Wu; Jean Simon; Elisabeth Le Bihan-Duval; Michel J Duclos; Larry A Cogburn Journal: PLoS One Date: 2015-10-07 Impact factor: 3.240